Clinical Evaluation of 18F-AV-1451
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Depression; Encephalopathy
- Focus Adverse reactions; Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 08 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 08 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 03 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.